X4 Pharmaceuticals Net Income
| XFOR Stock | USD 3.70 0.01 0.27% |
As of the 30th of January, X4 Pharmaceuticals owns the market risk adjusted performance of 1.44, and Standard Deviation of 5.41. In connection with fundamental indicators, the technical analysis model lets you check timely technical drivers of X4 Pharmaceuticals, as well as the relationship between them. Please check out X4 Pharmaceuticals market risk adjusted performance, variance, as well as the relationship between the Variance and potential upside to decide if X4 Pharmaceuticals is priced more or less accurately, providing market reflects its prevailing price of 3.7 per share. Given that X4 Pharmaceuticals has jensen alpha of 0.354, we strongly advise you to confirm X4 Pharmaceuticals's latest market performance to make sure the company can sustain itself sooner or later.
X4 Pharmaceuticals Total Revenue |
|
Gross Profit | Profit Margin | Market Capitalization | Enterprise Value Revenue 7.9956 | Revenue |
| Last Reported | Projected for Next Year | ||
| Net Loss | -86.8 M | -82.4 M | |
| Net Loss | -33.7 M | -35.4 M | |
| Net Loss | -33.7 M | -35.4 M | |
| Net Loss | (5.03) | (5.28) | |
| Net Income Per E B T | 1.16 | 1.11 |
XFOR | Net Income | Build AI portfolio with XFOR Stock |
Evaluating X4 Pharmaceuticals's Net Income across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into X4 Pharmaceuticals's fundamental strength.
Latest X4 Pharmaceuticals' Net Income Growth Pattern
Below is the plot of the Net Income of X4 Pharmaceuticals over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in X4 Pharmaceuticals financial statement analysis. It represents the amount of money remaining after all of X4 Pharmaceuticals operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is X4 Pharmaceuticals' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in X4 Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (37.45 M) | 10 Years Trend |
|
Net Income |
| Timeline |
XFOR Net Income Regression Statistics
| Arithmetic Mean | (40,481,838) | |
| Coefficient Of Variation | (74.32) | |
| Mean Deviation | 23,834,702 | |
| Median | (33,877,000) | |
| Standard Deviation | 30,086,733 | |
| Sample Variance | 905.2T | |
| Range | 87.9M | |
| R-Value | (0.64) | |
| Mean Square Error | 570T | |
| R-Squared | 0.41 | |
| Significance | 0.01 | |
| Slope | (3,813,708) | |
| Total Sum of Squares | 14483.4T |
XFOR Net Income History
Other Fundumenentals of X4 Pharmaceuticals
| Net Income Applicable To Common Shares | ||
| Net Income From Continuing Ops | ||
| Net Income Per Share | ||
| Net Income Per E B T |
X4 Pharmaceuticals Net Income component correlations
XFOR Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for X4 Pharmaceuticals is extremely important. It helps to project a fair market value of XFOR Stock properly, considering its historical fundamentals such as Net Income. Since X4 Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of X4 Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of X4 Pharmaceuticals' interrelated accounts and indicators.
Click cells to compare fundamentals
Can Biotechnology industry sustain growth momentum? Does XFOR have expansion opportunities? Factors like these will boost the valuation of X4 Pharmaceuticals. Anticipated expansion of XFOR directly elevates investor willingness to pay premium valuations. Determining accurate worth demands scrutiny of both present operating results and projected expansion capacity. Evaluating X4 Pharmaceuticals demands reviewing these metrics collectively while recognizing certain factors exert disproportionate influence.
Earnings Share (8.92) | Revenue Per Share | Quarterly Revenue Growth 2.152 | Return On Assets | Return On Equity |
Investors evaluate X4 Pharmaceuticals using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating X4 Pharmaceuticals' intrinsic value—the estimated true worth—helps identify when the stock trades at a discount or premium to fair value. Market participants employ diverse analytical approaches to determine fair value and identify buying opportunities when prices dip below calculated worth. External factors like market trends, sector rotation, and investor psychology can cause X4 Pharmaceuticals' market price to deviate significantly from intrinsic value.
Please note, there is a significant difference between X4 Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if X4 Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Conversely, X4 Pharmaceuticals' market price signifies the transaction level at which participants voluntarily complete trades.
X4 Pharmaceuticals 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to X4 Pharmaceuticals' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of X4 Pharmaceuticals.
| 11/01/2025 |
| 01/30/2026 |
If you would invest 0.00 in X4 Pharmaceuticals on November 1, 2025 and sell it all today you would earn a total of 0.00 from holding X4 Pharmaceuticals or generate 0.0% return on investment in X4 Pharmaceuticals over 90 days. X4 Pharmaceuticals is related to or competes with Aligos Therapeutics, Karyopharm Therapeutics, Kezar Life, Senti Biosciences, INmune Bio, Skye Bioscience, and OnKure Therapeutics. X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and com... More
X4 Pharmaceuticals Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure X4 Pharmaceuticals' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess X4 Pharmaceuticals upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 4.12 | |||
| Information Ratio | 0.0584 | |||
| Maximum Drawdown | 36.44 | |||
| Value At Risk | (5.21) | |||
| Potential Upside | 9.63 |
X4 Pharmaceuticals Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for X4 Pharmaceuticals' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as X4 Pharmaceuticals' standard deviation. In reality, there are many statistical measures that can use X4 Pharmaceuticals historical prices to predict the future X4 Pharmaceuticals' volatility.| Risk Adjusted Performance | 0.0593 | |||
| Jensen Alpha | 0.354 | |||
| Total Risk Alpha | (0.01) | |||
| Sortino Ratio | 0.0767 | |||
| Treynor Ratio | 1.43 |
X4 Pharmaceuticals January 30, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.0593 | |||
| Market Risk Adjusted Performance | 1.44 | |||
| Mean Deviation | 3.51 | |||
| Semi Deviation | 3.78 | |||
| Downside Deviation | 4.12 | |||
| Coefficient Of Variation | 1433.1 | |||
| Standard Deviation | 5.41 | |||
| Variance | 29.22 | |||
| Information Ratio | 0.0584 | |||
| Jensen Alpha | 0.354 | |||
| Total Risk Alpha | (0.01) | |||
| Sortino Ratio | 0.0767 | |||
| Treynor Ratio | 1.43 | |||
| Maximum Drawdown | 36.44 | |||
| Value At Risk | (5.21) | |||
| Potential Upside | 9.63 | |||
| Downside Variance | 16.94 | |||
| Semi Variance | 14.27 | |||
| Expected Short fall | (4.37) | |||
| Skewness | 1.54 | |||
| Kurtosis | 5.56 |
X4 Pharmaceuticals Backtested Returns
X4 Pharmaceuticals retains Efficiency (Sharpe Ratio) of -0.0122, which attests that the company had a -0.0122 % return per unit of price deviation over the last 3 months. X4 Pharmaceuticals exposes twenty-nine different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please check out X4 Pharmaceuticals' standard deviation of 5.41, and Market Risk Adjusted Performance of 1.44 to validate the risk estimate we provide. The firm owns a Beta (Systematic Risk) of 0.26, which attests to not very significant fluctuations relative to the market. As returns on the market increase, X4 Pharmaceuticals' returns are expected to increase less than the market. However, during the bear market, the loss of holding X4 Pharmaceuticals is expected to be smaller as well. At this point, X4 Pharmaceuticals has a negative expected return of -0.0575%. Please make sure to check out X4 Pharmaceuticals' potential upside, and the relationship between the jensen alpha and accumulation distribution , to decide if X4 Pharmaceuticals performance from the past will be repeated sooner or later.
Auto-correlation | 0.00 |
No correlation between past and present
X4 Pharmaceuticals has no correlation between past and present. Overlapping area represents the amount of predictability between X4 Pharmaceuticals time series from 1st of November 2025 to 16th of December 2025 and 16th of December 2025 to 30th of January 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of X4 Pharmaceuticals price movement. The serial correlation of 0.0 indicates that just 0.0% of current X4 Pharmaceuticals price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.0 | |
| Spearman Rank Test | -0.18 | |
| Residual Average | 0.0 | |
| Price Variance | 0.06 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
XFOR Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, X4 Pharmaceuticals reported net income of (37.45 Million). This is 110.97% lower than that of the Biotechnology sector and 153.47% lower than that of the Health Care industry. The net income for all United States stocks is 106.56% higher than that of the company.
XFOR Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses X4 Pharmaceuticals' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of X4 Pharmaceuticals could also be used in its relative valuation, which is a method of valuing X4 Pharmaceuticals by comparing valuation metrics of similar companies.X4 Pharmaceuticals is currently under evaluation in net income category among its peers.
X4 Pharmaceuticals Current Valuation Drivers
We derive many important indicators used in calculating different scores of X4 Pharmaceuticals from analyzing X4 Pharmaceuticals' financial statements. These drivers represent accounts that assess X4 Pharmaceuticals' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of X4 Pharmaceuticals' important valuation drivers and their relationship over time.
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 (projected) | ||
| Market Cap | 51.0M | 61.4M | 149.1M | 147.5M | 132.8M | 69.7M | |
| Enterprise Value | 9.0M | (21.9M) | 108.2M | 169.9M | 152.9M | 160.6M |
X4 Pharmaceuticals ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, X4 Pharmaceuticals' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to X4 Pharmaceuticals' managers, analysts, and investors.Environmental | Governance | Social |
X4 Pharmaceuticals Institutional Holders
Institutional Holdings refers to the ownership stake in X4 Pharmaceuticals that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of X4 Pharmaceuticals' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing X4 Pharmaceuticals' value.| Shares | Pale Fire Capital Se | 2025-06-30 | 60.1 K | Geode Capital Management, Llc | 2025-06-30 | 49.1 K | Squarepoint Ops Llc | 2025-06-30 | 39 K | Susquehanna International Group, Llp | 2025-06-30 | 34.8 K | Aqr Capital Management Llc | 2025-06-30 | 26.4 K | Point72 Asset Management, L.p. | 2025-06-30 | 21.7 K | Goldman Sachs Group Inc | 2025-06-30 | 18.9 K | Renaissance Technologies Corp | 2025-06-30 | 17.4 K | State Street Corp | 2025-06-30 | 15.5 K | Bain Capital Life Sciences Investors, Llc | 2025-06-30 | 563.9 K | Kingdon Capital Management Llc | 2025-06-30 | 233.3 K |
XFOR Fundamentals
| Return On Equity | -1.57 | ||||
| Return On Asset | -0.34 | ||||
| Profit Margin | (2.80) % | ||||
| Operating Margin | (12.81) % | ||||
| Current Valuation | 271.68 M | ||||
| Shares Outstanding | 87.44 M | ||||
| Shares Owned By Insiders | 1.15 % | ||||
| Shares Owned By Institutions | 38.47 % | ||||
| Number Of Shares Shorted | 3.09 M | ||||
| Price To Book | 5.14 X | ||||
| Price To Sales | 9.50 X | ||||
| Revenue | 2.56 M | ||||
| Gross Profit | 28.28 M | ||||
| EBITDA | (27.58 M) | ||||
| Net Income | (37.45 M) | ||||
| Cash And Equivalents | 47.38 M | ||||
| Cash Per Share | 0.69 X | ||||
| Total Debt | 78.09 M | ||||
| Debt To Equity | 1.28 % | ||||
| Current Ratio | 2.39 X | ||||
| Book Value Per Share | 2.45 X | ||||
| Cash Flow From Operations | (130.9 M) | ||||
| Short Ratio | 4.21 X | ||||
| Earnings Per Share | (8.92) X | ||||
| Target Price | 8.0 | ||||
| Number Of Employees | 143 | ||||
| Beta | 0.42 | ||||
| Market Capitalization | 322.64 M | ||||
| Total Asset | 146.45 M | ||||
| Retained Earnings | (515.36 M) | ||||
| Working Capital | 79.3 M | ||||
| Net Asset | 146.45 M |
About X4 Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze X4 Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of X4 Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of X4 Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with X4 Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if X4 Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in X4 Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving against XFOR Stock
| 0.36 | RNAZ | Transcode Therapeutics | PairCorr |
| 0.36 | CLRB | Cellectar Biosciences | PairCorr |
| 0.32 | IPHA | Innate Pharma | PairCorr |
| 0.31 | CRBP | Corbus Pharmaceuticals | PairCorr |
The ability to find closely correlated positions to X4 Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace X4 Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back X4 Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling X4 Pharmaceuticals to buy it.
The correlation of X4 Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as X4 Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if X4 Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for X4 Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for XFOR Stock Analysis
When running X4 Pharmaceuticals' price analysis, check to measure X4 Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy X4 Pharmaceuticals is operating at the current time. Most of X4 Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of X4 Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move X4 Pharmaceuticals' price. Additionally, you may evaluate how the addition of X4 Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.